|
Treatment of lower-risk myelodysplastic syndromes |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Diagnosis of myelodysplastic syndromes: the classic and the novel |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Drug development in higher-risk myelodysplastic syndromes |
Oct 2024 |
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Oct 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Oct 2024 |
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
Sep 2024 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
Sep 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
Sep 2024 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
